Valuation: Armata Pharmaceuticals, Inc.

Market Cap 122M 109M 100M 91.03M 170M 11.58B 173M 1.2B 481M 6.09B 458M 448M 19.21B P/E 2026 *
-1.76x
P/E 2027 * -2.27x
Enterprise Value 122M 109M 100M 91.03M 170M 11.58B 173M 1.2B 481M 6.09B 458M 448M 19.21B EV / Sales 2026 *
28.7x
EV / Sales 2027 * 44.3x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day+0.92%
1 week-9.89%
Current month-10.63%
1 month-10.63%
3 months-31.38%
6 months-67.13%
Current year-47.77%
1 week 3.15
Extreme 3.15
3.84
1 month 2.74
Extreme 2.745
4.07
Current year 2.74
Extreme 2.745
14.98
1 year 2.74
Extreme 2.745
14.98
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 66 12/02/2020
Director/Board Member 62 09/05/2019
Chairman 75 01/06/2021
Date Insider Type Main position Quantity % Market Cap. Importance
10/7/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/4/26 Free

Director

51,280 0.1400%
14/3/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%-9.89%-33.87%+44.49% 121M
-0.62%-1.87%+46.31%+56.99% 64.38B
+0.35%+3.20%+14.92%+84.55% 56.16B
+0.53%+1.96%+15.37%+106.81% 54.16B
-2.81%-4.31%+23.50%+50.90% 45.33B
-0.33%-1.93%+20.15%+98.45% 42.25B
+0.55%+2.31%+224.97%+942.56% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.44%+14.89%+47.15% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average +0.18%+3.36%+46.05%+151.64% 39.28B
Weighted average by Cap. +0.02%+3.27%+52.28%+161.95%

Financials

2026 *2027 *
Net sales 4.25M 3.81M 3.5M 3.17M 5.93M 404M 6.04M 41.75M 16.76M 212M 15.95M 15.61M 669M 2.75M 2.46M 2.27M 2.05M 3.84M 261M 3.91M 27.02M 10.85M 137M 10.32M 10.1M 433M
Net income -76.6M -68.6M -63.1M -57.18M -107M -7.27B -109M -753M -302M -3.83B -287M -281M -12.07B -72M -64.48M -59.31M -53.74M -100M -6.84B -102M -707M -284M -3.6B -270M -264M -11.34B
Net Debt - -
Projected Income Statement - Annual - Armata Pharmaceuticals, Inc.
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
30/10/26 US$3.280 +0.92% 46,741
29/10/26 US$3.250 -1.22% 102,950
28/10/26 US$3.290 -5.73% 62,135
27/10/26 US$3.490 +1.16% 104,310
26/10/26 US$3.450 -5.22% 63,646
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Armata Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.280USD
Average target price
17.50USD
Spread / Average Target
+433.54%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Armata Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARMP Stock